+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)

Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP)

American Journal of Hematology 77(2): 171-176

Plasma exchange is the standard treatment for thrombotic thrombocytopenic purpura (TTP). For patients refractory to plasma exchange, treatment options are limited and often unsuccessful. The platelet thrombi that form in acquired TTP are believed to result from the presence of procoagulant ultralarge multimers of von Willebrand factor (VWF) in the circulation due to autoantibody inhibition of VWF cleaving protease (ADAMTS-13), the enzyme that normally cleaves the ultralarge multimers. Rituximab, a chimeric monoclonal antibody against CD20, has been recognized as a useful therapy for antibody-mediated autoimmune disease. We therefore treated four patients with recurrent TTP with 2 or 4 weekly doses of rituximab in addition to corticosteroids, vincristine, plasma, or continuing plasma exchange. Three patients responded with prompt improvement in microangiopathic hemolytic anemia and thrombocytopenia, which allowed plasma exchange to be discontinued or avoided and prednisone to be rapidly discontinued. Two of the 3 responders have remained in unmaintained complete remission for 13+ months. The third patient relapsed at 13 months; a second course of rituximab and prednisone resulted in an unmaintained remission for 6+ months. All four patients were tested for ADAMTS-13 activity and its inhibitor at a point in their course when samples were available. Low ADAMTS-13 activity was noted in 3 patients tested at relapse, and the inhibitor activity was detectable in 2 patients. ADAMTS-13 activity increased during remission in one of these 2 patients although the patient had a persistence of the inhibitor. One patient tested only during remission had a normal ADAMTS-13 level. We conclude that rituximab may have a role and deserves further study in the treatment of patients with relapsing TTP. Copyright 2004 Wiley-Liss, Inc.

(PDF emailed within 0-6 h: $19.90)

Accession: 012522420

Download citation: RISBibTeXText

PMID: 15389904

DOI: 10.1002/ajh.20166

Related references

Rituximab for the Treatment of Relapsing/Refractory Thrombotic Thrombocytopenic Purpura. Blood 100(11): Abstract No 2703, November 16, 2002

Efficacy and safety of rituximab therapy for refractory/relapsing thrombotic thrombocytopenic purpura. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 35(1): 116-120, 2014

Efficacy and Safety of Rituximab for Refractory and Relapsing Thrombotic Thrombocytopenic Purpura: A Cohort of 10 Cases. Clinical Medicine Insights. Blood Disorders 8(): 1-7, 2015

Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. British Journal of Haematology 136(3): 451-461, 2007

Relapsing or refractory idiopathic thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: the role of rituximab. Transfusion 50(12): 2753-2760, 2011

Another beneficial effect of rituximab on refractory and relapsing thrombotic thrombocytopenic purpura: the role of interleukin-12 suppression?. Critical Care Medicine 40(4): 1391-1391, 2012

Rituximab provided long-term remission in a patient with refractory relapsing thrombotic thrombocytopenic purpura. International Journal of Hematology 81(5): 433-436, 2005

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases. American Journal of Hematology 78(1): 49-54, 2004

Rituximab for managing relapsing or refractory patients with idiopathic thrombotic thrombocytopenic purpura--haemolytic uraemic syndrome. Blood Transfusion 8(3): 203-210, 2010

Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study. Transfusion and Apheresis Science 43(3): 299-303, 2011

Successful treatment of relapsing autoimmune thrombotic thrombocytopenic purpura with rituximab. Pediatrics International 56(6): 914-918, 2016

Efficacy of rituximab in acute refractory or chronic relapsing non-familial idiopathic thrombotic thrombocytopenic purpura: a systematic review with pooled data analysis. Journal of Thrombosis and Thrombolysis 34(3): 347-359, 2013

Successful treatment with rituximab in a patient with refractory thrombotic thrombocytopenic purpura refractory to plasma exchange. Japanese Journal of Clinical Hematology 51(2): 127-131, 2010

Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literature. European Journal of Haematology 83(4): 365-372, 2009

High activity of rituximab for treatment of relapsed/refractory thrombotic thrombocytopenic purpura. Blood 102(11): 802a, November 16, 2003